undamentalytics Newsletter
Sign in

Aquestive Therapeutics, Inc. revenue

Aquestive Therapeutics, Inc.'s revenue was $44.5m in fiscal 2025, down 22.6% on the year before. Since fiscal 2017 ($66.9m) it has grown at a compound -5.0% a year. Over the last twelve months it was $54.1m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue67675346514851584554
Growth on the year before—+0.8%−22.0%−12.8%+10.9%−6.2%+6.1%+13.8%−22.6%—
Gross profit——3233—2830402636
Gross margin——61.3%71.7%—59.3%58.8%69.0%58.3%67.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Manufacture and Supply Revenue $40.2M ▲ 0.6%
License and Royalty Revenue $3.5M ▼ 77.1%
Co Development and Research Fees $1.3M ▼ 33.6%
Royalty $938,000 ▼ 6.9%
Proprietary Product Revenue -$478,000 ▼ 251.7%

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue Share YoY
United States $29.6M 66.5% ▼ 25.9%
Outside the US $14.9M 33.5% ▼ 15.3%

From Aquestive Therapeutics, Inc.'s 10-K filed March 4, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Aquestive Therapeutics, Inc. $54.1m 22.6% 5.2%
Aytu Biopharma, Inc $57.6m -13.3% -18.8%
Biofrontera Inc. $46.2m 17.8% 16.7%
Journey Medical Corp $68.2m 20.9% 3.5%
Rockwell Medical, Inc. $69.4m -21.1% -2.9%
Cumberland Pharmaceuticals Inc $39.9m -5.2% -0.6%

Compare with peers

Head to head: AQST vs AYTUAQST vs BFRIAQST vs DERMAQST vs RMTI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aquestive Therapeutics, Inc.